These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 11221020)

  • 21. Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer.
    Argiris A; Kut V; Luong L; Avram MJ
    Invest New Drugs; 2006 May; 24(3):203-12. PubMed ID: 16096702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia.
    Jatoi A; Tirona MT; Cha SS; Alberts SR; Rowland KM; Morton RF; Nair S; Kardinal CG; Stella PJ; Mailliard JA; Sargen D; Goldberg RM
    Int J Gastrointest Cancer; 2002; 32(2-3):115-23. PubMed ID: 12794247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A phase I study of gemcitabine and irinotecan as second line treatment for advanced non-small cell lung cancer].
    Ryo H; Toyama K; Isobe K; Sugino K; Sano G; Yamada H; Hiroi M; Hojyo T; Kimura K
    Gan To Kagaku Ryoho; 2003 Feb; 30(2):237-42. PubMed ID: 12610872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
    Kulke MH; Tempero MA; Niedzwiecki D; Hollis DR; Kindler HL; Cusnir M; Enzinger PC; Gorsch SM; Goldberg RM; Mayer RJ
    J Clin Oncol; 2009 Nov; 27(33):5506-12. PubMed ID: 19858396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I trial of docetaxel and gemcitabine in patients with advanced cancer.
    Rischin D; Boyer M; Smith J; Millward M; Michael M; Bishop J; Zalcberg J; Davison J; Emmett E; McClure B
    Ann Oncol; 2000 Apr; 11(4):421-6. PubMed ID: 10847460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
    Valero V
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):34-6. PubMed ID: 9364540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
    Goel A; Grossbard ML; Malamud S; Homel P; Dietrich M; Rodriguez T; Mirzoyev T; Kozuch P
    Anticancer Drugs; 2007 Mar; 18(3):263-71. PubMed ID: 17264757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.
    Rachamalla R; Malamud S; Grossbard ML; Mathew S; Dietrich M; Kozuch P
    Anticancer Drugs; 2004 Mar; 15(3):211-7. PubMed ID: 15014353
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial.
    Reni M; Panucci MG; Passoni P; Bonetto E; Nicoletti R; Ronzoni M; Zerbi A; Staudacher C; Di Carlo V; Villa E
    Cancer Invest; 2004; 22(5):688-96. PubMed ID: 15581049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study.
    Georgoulias V; Kouroussis C; Agelidou A; Boukovinas I; Palamidas P; Stavrinidis E; Polyzos A; Syrigos K; Veslemes M; Toubis M; Ardavanis A; Tselepatiotis E; Vlachonikolis I;
    Br J Cancer; 2004 Aug; 91(3):482-8. PubMed ID: 15238986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies.
    Mekhail T; Hutson TE; Elson P; Budd GT; Srkalovic G; Olencki T; Peereboom D; Pelley R; Bukowski RM
    Cancer; 2003 Jan; 97(1):170-8. PubMed ID: 12491518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor.
    Kornek GV; Haider K; Kwasny W; Raderer M; Schüll B; Payrits T; Depisch D; Kovats E; Lang F; Scheithauer W
    Clin Cancer Res; 2002 May; 8(5):1051-6. PubMed ID: 12006518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors.
    Couteau C; Risse ML; Ducreux M; Lefresne-Soulas F; Riva A; Lebecq A; Ruffié P; Rougier P; Lokiec F; Bruno R; Armand JP
    J Clin Oncol; 2000 Oct; 18(20):3545-52. PubMed ID: 11032597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors.
    Rothenberg ML; Sharma A; Weiss GR; Villalona-Calero MA; Eckardt JR; Aylesworth C; Kraynak MA; Rinaldi DA; Rodriguez GI; Burris HA; Eckhardt SG; Stephens CD; Forral K; Nicol SJ; Von Hoff DD
    Ann Oncol; 1998 Jul; 9(7):733-8. PubMed ID: 9739439
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
    Kosmas C; Tsavaris N; Syrigos K; Koutras A; Tsakonas G; Makatsoris T; Mylonakis N; Karabelis A; Stathopoulos GP; Kalofonos HP
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):51-9. PubMed ID: 16622691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I study of gemcitabine and docetaxel for advanced stage solid tumors.
    Poole ME; Bernard SA; Churchel MA; Weissler MC; Calvo B; Cance W; Ollila D; Koruda M; Behrns K; Detterbeck FC
    Cancer Invest; 2003 Jun; 21(3):350-4. PubMed ID: 12901280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks.
    Alberts SR; Erlichman C; Sloan J; Okuno SH; Burch PA; Rubin J; Pitot HC; Goldberg RM; Adjei AA; Atherton PJ; Kaufmann SH
    Ann Oncol; 2001 May; 12(5):627-31. PubMed ID: 11432620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.
    Ko AH; Dito E; Schillinger B; Venook AP; Bergsland EK; Tempero MA
    Cancer Invest; 2008 Feb; 26(1):47-52. PubMed ID: 18181045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors.
    Dumez H; Louwerens M; Pawinsky A; Planting AS; de Jonge MJ; Van Oosterom AT; Highley M; Guetens G; Mantel M; de Boeck G; de Bruijn E; Verweij J
    Anticancer Drugs; 2002 Jul; 13(6):583-93. PubMed ID: 12172503
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.
    Lockhart AC; Bauer TM; Aggarwal C; Lee CB; Harvey RD; Cohen RB; Sedarati F; Nip TK; Faessel H; Dash AB; Dezube BJ; Faller DV; Dowlati A
    Invest New Drugs; 2019 Feb; 37(1):87-97. PubMed ID: 29781056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.